Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 2/20 | 0.49 |
| ▸ | CDK8 | P49336 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17761437 | 0.95 | CCNC (0.47) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL9948300 | 0.92 | USP30 (0.47) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL30690042 | 0.92 | USP30 (0.47) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL2020246 | 0.92 | CCNC (0.44) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL31006330 | 0.90 | CCNC (0.43) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL769742 | 0.87 | USP2 (0.45) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL18113438 | 0.87 | CCNC (0.41) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL20543938 | 0.86 | USP2 (0.42) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL31748166 | 0.85 | MAPT (0.42) | CCNCCDK8USP2SMN1; SMN2KDM4E | |
| SCHEMBL16914452 | 0.84 | USP2 (0.43) | CCNCCDK8USP2SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586257-A | Compound containing 2, 8-diazaspiro [4.5] decan-1-one skeleton and application thereof | 中国药科大学 | 2024-02-23 | — | — | CN | claimed |
| EP-4618755-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12410194-B2 | Potent and selective azaindole inhibitors of CDK8 and CDK19 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| CN-114369095-B | Aminopyrimidine compounds useful as SSAO inhibitors and methods for preparing the same | 伊莱利利公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-4415706-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240239781-A1 | 1H-PYRAZOLE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-07-18 | — | — | US | disclosed |
| CN-113493441-B | Novel spiro compound and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024107746-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES (US) | 2024-05-23 | — | — | WO | disclosed |
| US-7435831-B2 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435831-B2 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7288548-B2 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| EP-1419155-B1 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-20060074121-A1 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2006-04-06 | — | — | US | disclosed |
| US-20050234034-A1 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2005-10-20 | — | — | US | disclosed |
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
| US-20050070563-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2005-03-31 | — | — | US | disclosed |
| US-20040198756-A1 | Medicaments | SMITHKLINE BEECHAM PLC (GB) | 2004-10-07 | — | — | US | disclosed |
| WO-2000027790-A1 | MUTILIN COMPOUNDS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | CCNC 4804/4885CDK8 2747/4885USP2 2620/4885 |
| US-20050234034-A1 | Bicyclic and bridged nitrogen heterocycles | CCR3, CCR1, CCR2 | CCNC 483/4885CDK8 920/4885USP2 4532/4885 |
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | CCNC 2131/4885CDK8 2423/4885USP2 4697/4885 |
| US-20050070563-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CCR5, CXCR2 | CCNC 1975/4885CDK8 2097/4885USP2 4683/4885 |
| US-20060074121-A1 | Bicyclic and bridged nitrogen heterocycles | CCR3, CCR1, CCR2 | CCNC 483/4885CDK8 920/4885USP2 4532/4885 |
| US-20040198756-A1 | Medicaments | PIGO, PSAP, CD68 | CCNC 4722/4885CDK8 4854/4885USP2 2709/4885 |
| US-20240239781-A1 | 1H-PYRAZOLE DERIVATIVES AS SIGMA LIGANDS | SIGMAR1, TMEM97, OPRD1 | CCNC 4047/4885CDK8 3132/4885USP2 3638/4885 |
| US-12410194-B2 | Potent and selective azaindole inhibitors of CDK8 and CDK19 | CDK8, CDK9, CDK19 | CCNC 43/4885CDK8 1/4885USP2 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.